^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Title:

Pan-RAF Inhibition Shows Anti-Leukemic Activity in RAS-Mutant Acute Myeloid Leukemia Cells and Potentiates the Effect of Sorafenib in Cells with FLT3 Mutation

Published date:
11/25/2020
Excerpt:
...the combination of LY3009120 and sorafenib resulted in significantly higher levels of apoptosis in AML cells with heterozygous and hemizygous FLT3 mutations...
DOI:
10.3390/cancers12123511